Renolife Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 1.10 M
as on 30-07-2024
- Paid Up Capital ₹ 1.05 M
as on 30-07-2024
- Company Age 16 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 18.19%
(FY 2023)
- Profit -13.64%
(FY 2023)
- Ebitda -16.39%
(FY 2023)
- Net Worth 15.73%
(FY 2023)
- Total Assets 38.18%
(FY 2023)
About Renolife Pharma (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.10 M and a paid-up capital of Rs 1.05 M, as per Ministry of Corporate Affairs (MCA) records.
Tirunilayi Venugopal, Pudugrammam Vaidyanathan, Ajitkumar Warrior, and Four other members serve as directors at the Company.
- CIN/LLPIN
U52310KL2008PTC023384
- Company No.
023384
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Nov 2008
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Nurani Post, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Renolife Pharma (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kandamkulathy Lazar  | Managing Director | 10-Nov-2008 | Current |
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pudugrammam Vaidyanathan | Director | 11-Jun-2010 | Current |
| Tirunilayi Venugopal | Director | 11-Jun-2010 | Current |
| Ajitkumar Warrior | Director | 11-Jun-2010 | Current |
| Shaji Thuvakkunnon | Director | 11-Jun-2010 | Current |
| Pariyarath Nandakumar | Director | 11-Jun-2010 | Current |
| Mullothu Krishnakumar | Director | 11-Jun-2010 | Current |
Financial Performance of Renolife Pharma (India).
Renolife Pharma (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 18.19% increase. The company also saw a substantial fall in profitability, with a 13.64% decrease in profit. The company's net worth Soared by an impressive increase of 15.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Renolife Pharma (India)?
In 2023, Renolife Pharma (India) had a promoter holding of 71.51% and a public holding of 28.49%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
R-Vision Eye Hospital Private LimitedActive 5 years 10 monthsTirunilayi Venugopal and Pudugrammam Vaidyanathan are mutual person
Rhine Biogenics Private LimitedActive 21 years 2 monthsTirunilayi Venugopal, Pudugrammam Vaidyanathan and 1 more are mutual person
Rineus Health Care Company Private LimitedActive 12 years 7 monthsTirunilayi Venugopal, Pudugrammam Vaidyanathan and 1 more are mutual person
- Rhine Life Sciences Private LimitedActive 18 years 6 months
Tirunilayi Venugopal, Pudugrammam Vaidyanathan and 1 more are mutual person
- Moselle Drugs And Cosmetics LimitedActive 5 years 11 months
Pudugrammam Vaidyanathan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Renolife Pharma (India)?
Unlock and access historical data on people associated with Renolife Pharma (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Renolife Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Renolife Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
